Disposition of tiludronate (Skelid®) in animals

Xenobiotica

Volumn 29, Issue 10, 1999, Pages 1017-1031

  Davi, H ^a   Tronquet, C ^a   Caix, J ^a   Simiand, J ^a   Briot, C ^a   Berger, Y ^a   Thiercelin, J F ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PLASMA PROTEIN; SERUM ALBUMIN; TILUDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BABOON; BINDING AFFINITY; CALCIFICATION; CORTICAL BONE; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG RELEASE; DRUG URINE LEVEL; FEMALE; FOOD INTAKE; GASTROINTESTINAL ABSORPTION; INTRAVENOUS DRUG ADMINISTRATION; LONG BONE; MALE; MONKEY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PLASMA CLEARANCE; RABBIT; RAT; TRABECULAR BONE;

AGING; ANIMALS; BLOOD PROTEINS; BONE AND BONES; BONE RESORPTION; DIPHOSPHONATES; DOGS; FEMALE; FOOD; HAPLORHINI; INTESTINAL ABSORPTION; MALE; MICE; PAPIO; PROTEIN BINDING; RABBITS; RATS; TISSUE DISTRIBUTION;

ANIMALIA; CANIS FAMILIARIS; ORYCTOLAGUS CUNICULUS; PAPIO HAMADRYAS;

EID: 0032697899     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982599238083     Document Type: Article

References (32)

1. AMMANN, P., RIZZOLI, R., CAVERZASIO, J., ShIGEMATSU T., SLOSMAN, D. and BONJOUR, J. P., 1993, Effects of the bisphophonate tiludronate on bone resorption, calcium balance and bone mineral density. Journal of Bone and Mineral Research, 8, 1491-1498.
2. BARBIER, A., EMONDS-ALT, X., BRELIERE, J. C. and ETHGEN, D., 1990, In vitro and in vivo osseous pharmacological profile of tiludronate. Implication for osteoporosis treatment. Osteoporosis, 2, 1127-1129.
3. 14C-tiludronate in rats. Bone, 16 (suppl.), 228S.
4. BOULENC, X., MARTI, E., JOYEUX, H., ROQUES, C., BERGER, Y. and FABRE, G., 1993, Importance of the paracellular pathway for thc transport of new bisphophonates using the human Caco-2 monolayers model. Biochemical Pharmacology, 46, 1591 1600.
5. BOULENC, X., ROQUES, C., JOYEUX, H., BERGER, Y. and FABRE, G., 1995, Bisphophonates increase tight junctions permeability in the human intestinal epithelial (Caco-2) model. International Journal of Pharmaceutics, 123, 13-24.
6. 14C-labelled ADP and 99m Tc-labelled ADP in the mouse. Calcified Tissue International, 43, 125-127.
7. DALEY-YATES, P. T., DODWELL, D. J., PONGCHAIDECHA, M., COLEMAN, R. E. and HOWELL, A., 1991, Thc clearance and bioavailahility of pamidronate in patients with breast cancer and bone metastasis. Calcified Tissue International, 9, 433-435.
8. 1-ATPase. Journal of Bone and Mineral Research, 11, 1498-1507.
9. DE VERNEJOUL. M. C., JIANG, Y., LACHERETZ, F., BARBIER, A., GEUSENS, P., MORIEUX, C. and PFERSDORFF, C., 1990, Prevention of bone loss following tiludronate administration to ovariectomized beagle dogs. Osteoporosis, 2, 1119-1122.
10. DELMAS, P., VERGNAUD, P., ARLOT, M., PASTOUREAU, P. and MEUNIER, P., 1991, The in vivo anabolic effect of hPTH is blunted when bone resorption is blocked by a bisphophonate. Journal of Bone and Mineral Research, 6 (suppl. 1), S136.
11. FELS, J.P., GUYONNET, J., BERGER, Y. and CAUTREELS, W., 1988, Determination of (4-chlorophenyl)thiomethylene bisphosphonic acid, a new bisphosphonate, in biological fluids by high-performance liquid chromatography. Journal of Chromatography, Biomedical Applications, 430, 73-79.
12. FLEISCH, IL., 1995, Bisphosphonates in bone disease. In From the Laboratory to the Patients, 2nd edn (Berne: Parthenon), pp. 11-30.
13. GERTZ, B. J., HOLLAND, S. D., KLINE, W. F., MATUSZEWSKI, B. K. and PORRAS, A. G., 1993, Clinical pharmacology of alendronate sodium. Osteoporosis International, 3 (suppl. 3), 513-516.
14. KASTING, G. B. AND FRANCIS, M. D., 1992, Retention of etidronate in human, dog and rat. Journal of Bone and Mineral Research, 7, 513-522.
15. LIN, J. H., 1996, Bisphosphonates: a review of their pharmacokinetic properties. Bone, 18, 75-85.
16. LIN, J. H., CHEN, I.-W. AND DELUNA, F. A., 1992, Effects ofdose, sex and age on the disposition of alendronate, a potent antiosteolytic bisphophonate, in rats. Drug Metabolism and Disposition, 20, 473-478.
17. LIN, J.H., CHEN, I. W. DELUNA, F. A., 1994, On the absorption of alendronate in rats. Journal of Pharmaceutical Science, 83, 1741-1746.
18. LIN, J. H., DUGGAN, D. E., CHEN, I.-W. AND ELLSWORTH, R. L., 1991, Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metabolism and Disposition, 19, 926-932.
19. MICHAEL, W. R., KING, W. R. AND WAKIM, J. M., 1972, Metabolism of disodium ethane-1-hydroxy-1, 1-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey. Toxicology and Applied Pharmacology, 21, 503-15.
20. 14C-clodronate in mice and rats. Pharmacological Toxicology, 62, 51-53.
21. MÖNKKÖNEN, J., KOPONEN, H.-M. AND YALITALO, P., 1989, Comparison of the distribution of three bisphosphonate in mice. Pharmacological Toxicology, 62, 294-298.
22. 14C] clodronate (dichloromethylene bisphosphonate) disodium in mice. Toxicology and Applied Pharmacology, 89, 287-292.
23. MURAKAMI, H., NAKAMURA, T., TSURUKAMI, H., ABE, M., BARBIER, A. AND SUZUKI K., 1994, Effects of tiludronate on bone mass, structure and turnover at the epiphyseal, the primary and the secondary spongiosae in the proximal tibia of growing rats after sciatic neurectomy, Journal of Bone and Mineral Research, 9, 1355-1364.
24. MURAKAMI, H., TAKAHASHI, N., SASAKI, T., UDAGAWA, N., TANAKA, S., NAKAMURA, L., ZHANG, D., BARBIER, A. and SUDA, T., 1995, A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone, 17, 137-144.
25. MURAKAMI, H., TAKAHASHI, N., TANAKA, S., NAKAMURA, L, UDAGAWA, N., NAKAJO, S., NAKAYA, K., ABE, M., YUDA, Y., KONNO, F., BARBIER, A. and SUDA, T., 1997, Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone, 20, 399-404.
26. RECKER, R. R. and SAVILLE, P. D., 1973, Intestinal absorption of disodium ethane-1-hydroxyl-1-diphosphonate (disodium etidronate) using a deconvulation technique. Toxicology and Applied Pharmacology, 24, 580-589.
27. SANSOM, L. N., NECCIARI, J. and THIERCELIN, J. F., 1995, Human pharmacokinetics of tiludronate. Bone, 17 (suppl.), S479-483.
28. SATO, M., GRASSER, W., ENDO, N., AKINS, R., SIMMONS, H., THOMPSON, D. D., GOLUD, E. and RODAN, G. A., 1991, Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastucture. Journal of Clinical Imbestigation, 88, 2095-2105.
29. SCHWIETERT, H. R., PEETERS, P. A. M., DINGEMANSE, J., THIERCELIN, J. F., NECCIARI, J., DE BRUIN, H. and JONKMAN, J. H. G., 1996, Multiple dose pharmacokinetics of tiludronate in healthy volunteers. European Journal of Clinical Pharmacology, 51, 175-181.
30. TWISS, I. M., DEWATER, R., DENHARTIGH, J., SPARIDANS, R., RAM-KOOPMANSCHAP, W., BRILL, H., WIJDEVELD M. and VERMEIJ, P., 1994, Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport. Journal of Pharmaceutical Sciences, 83, 699-703.
31. WINGEN, F. and SCHMÄHL, D., 1987, Pharmacokinetics of the osteotropic diphosphonate 3-amino-1-hydroxypropane-1, 1-diphosphonic acid in mammals. Arzneimittel-Forschung/Drug Research, 37, 1037-1042.
32. YAKATAN, G. Y., POYNOR, W. J., TALBERT, R. L., FLOYD, B. F., SLOUGH, C. L., AMPULSK, R. S. and BENEDICT, J. J., 1982, Clodronate kinetics and bioavailability. Clinical Pharmacology and Therapeutics, 31, 402-410.